Immune Targeting Systems turns sights on commercial goals
This article was originally published in Scrip
By hiring two industry veterans, Immune Targeting Systems has flagged its intention to shift its focus to include commercial goals. The UK biotech focusing on the development of vaccines that promote T-cell responses to viruses and cancers has announced the appointment of Dr Benjamin Chen as executive chairman and Dr Kevin Fitzgerald as chief operating officer. Armed with Phase I data from two trials of the company's lead pandemic flu programme, the new leadership team intends to step up biopartnering activities and find a new investor to lead its existing backers in a series B round.